NCODA Logo

Nubeqa Update – New Safety Data Poster Presented at ASCO

Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide Darolutamide is a structurally distinct androgen-receptor inhibitor that is approved for the treatment of nonmetastatic, castration-resistant prostate cancer. In the planned primary...